One Center's Experience: Demographics, Treatment, and Outcome of Patients With Adrenocortical Carcinoma (ACC) Treated During the Past 40 Years

Abstract

difference in acute and late gastrointestinal and genitourinary toxicities (modified Radiation Therapy Oncology Group [RTOG] definitions) were also assessed. Results: Between 2001 and 2012, 2301 men were treated with IMRT alone (median dose: 78 Gy); of these, 40% were low-, 36% intermediate-, and 24% high-risk, based on National Comprehensive Cancer Network criteria. MHS was reported in 232 men (10%); these men were less likely to have heart disease or diabetes (P<.05). MHSs contained a median of 3 identifiable ingredients (range, 0-30); the most common was saw palmetto (91%), followed by ingredients no different than standard multivitamins (5%), or no identifiable ingredients (4%). At a median follow-up time of 46 months (range 1e190 months), men taking an MHS had no difference compared to those not on MHSs in FFBF (among any risk group), CSS, or FFDM (Table). Differences in OS in men taking MHSs versus those not on MHSs were not significant after adjusting for risk covariates. RTOG acute and late toxicities were not different between the groups. Conclusion: MHS use is not associated with a change in cancer-related outcomes or toxicities in men receiving IMRT for prostate cancer.